Cingulate (CING) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cingulate (CING) has outperformed XBiotech (XBIT) over the past year, gaining 12.4% versus a loss of 11.9%. Cingulate is the larger company by market cap ($71.1 million vs $69.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | XBIT |
|---|---|---|
| Share price | $4.89 | $2.29 |
| Market cap | $71.11M | $69.82M |
| 1-day change | +0.20% | +4.09% |
| YTD return | +12.67% | -4.18% |
| 1-year return | +12.41% | -11.92% |
| 5-year return | — | -82.66% |
| Forward P/E | — | 17.62 |
| EPS (TTM) | $-3.51 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.89 | $3.44 |
| 52-week low | $3.16 | $2.09 |
| Distance from 52-week high | -58.87% | -33.43% |
| Analyst consensus | none | — |
| Avg. price target upside | +333.54% | — |
| Average volume | 133.48K | 40.80K |
| Shares outstanding | 14.54M | 30.49M |
| Employees | 14 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed XBIT by 24.3 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
CING vs XBIT FAQ
Which is bigger, Cingulate or XBiotech?
Cingulate (CING) is larger, with a market capitalization of $71.11M compared with $69.82M for XBiotech (XBIT).
Which stock has performed better over the past year, CING or XBIT?
CING returned +12.41% over the past 12 months, compared with -11.92% for XBIT (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.